Maven Securities’s Akebia Therapeutics AKBA Stock Holding History

Maven Securities’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-200,000	Closed	-$384K	–	790
2025 Q1	$384K	Buy	+200,000	New	+$408K	0.01%	655

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Maven Securities's AKBA Position: Q2 2025 in Review

Maven Securities sold out of Akebia Therapeutics (AKBA) in Q2 2025, closing a stake of 200,000 shares — an estimated $384K sold.

Maven Securities first reported a position in AKBA in Q1 2025 and held it in 1 quarter. The position peaked at $384K in Q1 2025. 157 funds tracked by Wall St. Rank hold AKBA as of Q2 2025.

Maven Securities reported no remaining Akebia Therapeutics position as of Q2 2025 after selling out during the quarter.
Maven Securities sold 200,000 Akebia Therapeutics shares in Q2 2025, an estimated $384K.
Maven Securities first reported a position in Akebia Therapeutics in Q1 2025 and held it in 1 quarter.
Maven Securities's Akebia Therapeutics position peaked at $384K in Q1 2025.
157 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2025.

Based on Maven Securities's 13F filing for Q2 2025, filed 14 Aug 2025.